Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / SPPI - Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside


SPPI - Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside

On December 26 before market open, Spectrum Pharmaceuticals (NASDAQ:SPPI) provided an update on its lead candidates poziotinib and ROLONTIS. The news was clearly not well-received, as the stock finished down 60% for the day.

The reason the stock crashed is because the phase 2 ZENITH20 trial of poziotinib in 2nd line NSCLC patients with EGFR exon 20 mutations did not meet the pre-specified primary endpoint in Cohort 1. Our original thesis was that even though the ORR had been declining at successive data readouts (down from an original high of 73%), it

Read more ...

Stock Information

Company Name: Spectrum Pharmaceuticals Inc.
Stock Symbol: SPPI
Market: NASDAQ
Website: sppirx.com

Menu

SPPI SPPI Quote SPPI Short SPPI News SPPI Articles SPPI Message Board
Get SPPI Alerts

News, Short Squeeze, Breakout and More Instantly...